These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30597161)

  • 1. RNA-Mediated Disease Mechanisms in Neurodegenerative Disorders.
    Neueder A
    J Mol Biol; 2019 Apr; 431(9):1780-1791. PubMed ID: 30597161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative splicing in neurodegenerative disease and the promise of RNA therapies.
    Nikom D; Zheng S
    Nat Rev Neurosci; 2023 Aug; 24(8):457-473. PubMed ID: 37336982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.
    Li D; McIntosh CS; Mastaglia FL; Wilton SD; Aung-Htut MT
    Transl Neurodegener; 2021 May; 10(1):16. PubMed ID: 34016162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI; Cheng K; Guntaka RV
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide-based therapy for neurodegenerative diseases.
    Magen I; Hornstein E
    Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Birth and death view of DNA, RNA, and proteins.
    Kumari P; Sarovar Bhavesh N
    Gene; 2023 Oct; 883():147672. PubMed ID: 37506987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau mis-splicing in the pathogenesis of neurodegenerative disorders.
    Park SA; Ahn SI; Gallo JM
    BMB Rep; 2016 Aug; 49(8):405-13. PubMed ID: 27222125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-mediated toxicity in neurodegenerative disease.
    Belzil VV; Gendron TF; Petrucelli L
    Mol Cell Neurosci; 2013 Sep; 56():406-19. PubMed ID: 23280309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making antisense of splicing.
    Garcia-Blanco MA
    Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of alternative splicing by antisense oligonucleotides.
    Sazani P; Kole R
    Prog Mol Subcell Biol; 2003; 31():217-39. PubMed ID: 12494768
    [No Abstract]   [Full Text] [Related]  

  • 12. [Perspectives of RNA interference application in the therapy of diseases associated with defects in alternative RNA splicing].
    Wysokiński D; Błasiak J
    Postepy Hig Med Dosw (Online); 2012 Sep; 66():683-95. PubMed ID: 23001210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of Antisense Drugs.
    Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau as a molecular marker of development, aging and neurodegenerative disorders.
    Hernández F; Pérez M; de Barreda EG; Goñi-Oliver P; Avila J
    Curr Aging Sci; 2008 Mar; 1(1):56-61. PubMed ID: 20021373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodegenerative tauopathies: human disease and transgenic mouse models.
    Lee VM; Trojanowski JQ
    Neuron; 1999 Nov; 24(3):507-10. PubMed ID: 10595503
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous nuclear ribonucleoprotein A1 in health and neurodegenerative disease: from structural insights to post-transcriptional regulatory roles.
    Bekenstein U; Soreq H
    Mol Cell Neurosci; 2013 Sep; 56():436-46. PubMed ID: 23247072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotides in therapy for neurodegenerative disorders.
    Evers MM; Toonen LJ; van Roon-Mom WM
    Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA metabolism in neurodegenerative disease.
    Liu EY; Cali CP; Lee EB
    Dis Model Mech; 2017 May; 10(5):509-518. PubMed ID: 28468937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA oxidation in Alzheimer disease and related neurodegenerative disorders.
    Nunomura A; Hofer T; Moreira PI; Castellani RJ; Smith MA; Perry G
    Acta Neuropathol; 2009 Jul; 118(1):151-66. PubMed ID: 19271225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau pathology: a marker of neurodegenerative disorders.
    Delacourte A; Buée L
    Curr Opin Neurol; 2000 Aug; 13(4):371-6. PubMed ID: 10970052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.